In advanced or metastatic NSCLC patients, 52.3% (34/65) primary BRAF-mutated patients and 93.3% (14/15) acquired BRAF-mutated patients (p=0.003) had concomitant oncogenic driver genes. Here, BRAF is linked to non-small cell lung carcinoma.